About Us
Company Profile
Vision Values & Promise
Management
Board of Directors
Executive Leadership Team
Locations Worldwide
Subsidiaries
Group Ombudsperson
Business Segments
Radiopharma
Allergy Immunotherapy
CDMO Sterile Injectables
Generics
Contract Research Development & Manufacturing Organisation
Drug Discovery Service
Active Pharmaceutical Ingredients
Proprietary Novel Drugs
Business Enablers
Manufacturing
R&D and Intellectual Property
Business Excellence
Human Resource
Supply Chain
Investors
Financials
Quarterly Results
Investor Presentation
Annual Reports
Annual Return
Subsidiaries Accounts
Intimation to Stock Exchanges
Investor Meets
Stock Information
Share Price Graph
Historical Share Price
Analyst Coverage
Listing
Sub Division of Shares
Equity History
Investor Information
Change of Name
Scheme of Arrangement
Share Holding Pattern
Share Transfer Information
Distribution Pattern
Dividend Payment
Cost Spilit Letter
FAQs
Forms
Updation of KYC details
Credit Ratings
Corporate Governance
Philosophy
Board Structure
Policies and Codes
Duties of Directors
Postal Ballot
Unclaimed Dividend & Shares
Investor Feedback Form
Investor Contact
Nodal Officer
Institutional Investors
Investor Grievances
Registrar and Transfer Agent
KMP - Reg. 30
Disclosure
Online Dispute Resolution
Sustainability
Overview
Corporate Social Responsibility
Sustainable Development Goals
Safety and Occupational Health
Stakeholder Engagement
Environment
Environmental Compliance
Fly Ash Stock Report
Policies
Climate Change Mitigation and Energy Conservation Policy
Environmental, Health and Safety Policy
Sustainability Policy
Biodiversity Policy
Biomedical Waste Information
Sustainability Report
Sustainability Contact
About Us
Company Profile
Vision Values & Promise
Management
Board of Directors
Shyam S Bhartia
Hari S Bhartia
Sushil Kumar Roongta
Vivek Mehra
Arun Seth
Shirish G. Belapure
Shivpriya Nanda
Harsh Mahajan
Priyavrat Bhartia
Arjun Shanker Bhartia
Arvind Chokhany
Jinang Pratap Parekh
Executive Leadership Team
Locations Worldwide
Subsidiaries
Group Ombudsperson
Business Segments
Radiopharma
Allergy Immunotherapy
CDMO Sterile Injectables
Generics
Contract Research Development & Manufacturing Organisation
Drug Discovery Service
Active Pharmaceutical Ingredients
Proprietary Novel Drugs
Business Enablers
Manufacturing
R&D and Intellectual Property
Business Excellence
Human Resource
Supply Chain
Investors
Financials
Quarterly Results
Investor Presentation
Annual Reports
Annual Return
Subsidiaries Accounts
Intimation to Stock Exchanges
Investor Meets
Stock Information
Share Price Graph
Historical Share Price
Analyst Coverage
Listing
Sub Division of Shares
Equity History
Investor Information
Change of Name
Scheme of Arrangement
Share Holding Pattern
Share Transfer Information
Distribution Pattern
Dividend Payment
Cost Spilit Letter
FAQs
Forms
Updation of KYC details
Credit Ratings
Corporate Governance
Philosophy
Board Structure
Policies and Codes
Policy on Materiality of Related Party Transactions and Dealing with Related Party Transactions
Policy on Board Diversity
Policy for Determining Material Subsidiaries
Whistle Blower Policy
Corporate Social Responsibility Policy
Code of Conduct for Directors and Senior Management
Code for Independent Directors
Appointment and Remuneration Policy
Familiarisation Programme for Independent Directors
Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information
Policy for Determination of Materiality of Events and Information
Archival Policy
Dividend Distribution Policy
Silent Period Policy
Corporate Tax Policy
Grievance Redressal policy
Risk Management Policy
Duties of Directors
Independence Criteria for Directors
Postal Ballot
Unclaimed Dividend & Shares
Investor Feedback Form
Investor Contact
Nodal Officer
Institutional Investors
Investor Grievances
Registrar and Transfer Agent
KMP - Reg. 30
Disclosure
Online Dispute Resolution
Sustainability
Overview
Corporate Social Responsibility
Sustainable Development Goals
Safety and Occupational Health
Stakeholder Engagement
Environment
Environmental Compliance
Fly Ash Stock Report
Policies
Climate Change Mitigation and Energy Conservation Policy
Environmental, Health and Safety Policy
Sustainability Policy
Biodiversity Policy
Biomedical Waste Information
Sustainability Report
Sustainability Contact
News
Careers
Global Opportunities
Code of Conduct
Fraud Alert Statement
Fun at Work
Diversity and Inclusion
Campus Hiring
Policies
Downloads
Brochures
Annual Report
Sustainability Report
Contact
Addresses
Enquiry Form
News
Careers
Global Opportunities
Code of Conduct
Fraud Alert Statement
Fun at Work
Diversity and Inclusion
Campus Hiring
Policies
Downloads
Brochures
Annual Report
Sustainability Report
Contact
Addresses
Enquiry Form
What are you looking for?
×
Financial Results on conclusion of Board Meeting
Home
Financial Results on conclusion of Board Meeting
Financial Results on conclusion of Board Meeting
2022-23
Q1
Q4 Results FY 2022 - May 27, 2022
Q2
Q1 Results FY 2023 - August 2, 2022
Q3
Q2 Results FY 2023 - October 21, 2022
Q4
Q3 Results FY 2023 - February 3, 2023
2021-22
Q1
Q4 Results FY 2021 - June 4, 2021
Q2
Q1 Results FY 2022 - July 23, 2021
Q3
Q2 Results FY 2022 - October 22, 2021
Q4
Q3 Results FY 2022 - February 4, 2022
2020-21
Q1
Q4 Results FY 2020 - May 29, 2020
Q2
Q1 Results FY 2021 - September 4, 2020
Q3
Q2 Results FY 2021 - November 4, 2020
Q4
Q3 Results FY 2021 - February 5, 2021
2019-20
Q1
JLL Standalone and Consolidated Results for the quarter and year ended March 31, 2019 - May 17, 2019
Q3
Q2 Results FY 2020 - October 25, 2019
2018-19
Q2
Q1 Results FY 2019 July 27, 2018
Q3
Q2 Results FY 2019 October 22, 2018
Q4
Q3 Results FY 2019 February 1, 2019